Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)

Estimated Value: $1,500,000
Open 536 days left Healthcaregrant
Nov 22, 2024
Dec 23, 2027 12:00 AM
Healthcare
grant
AI Summary
This grant opportunity, RFA-HL-26-017 (Catalyze), focuses on product definition for small molecules, biologics, and combination products, specifically target identification and validation, and preliminary product/lead series identification. Clinical trials are not allowed under this R61/R33 mechanism. The funding opportunity is associated with CFDA numbers 93.839, 93.838, 93.233, and 93.837.
Line Items
ItemQtyUnitEst. Unit PriceEst. TotalCategory
Target Identification and Validation Services for Small Molecules 1 lot $250,000.00 $250,000.00 Professional Services
Target Identification and Validation Services for Biologics 1 lot $250,000.00 $250,000.00 Professional Services
Target Identification and Validation Services for Combination Products 1 lot $250,000.00 $250,000.00 Professional Services
Preliminary Product/Lead Series Identification Services for Small Molecules 1 lot $250,000.00 $250,000.00 Professional Services
Preliminary Product/Lead Series Identification Services for Biologics 1 lot $250,000.00 $250,000.00 Professional Services
Preliminary Product/Lead Series Identification Services for Combination Products 1 lot $250,000.00 $250,000.00 Professional Services
Estimated Bid Value$1,500,000.00

Want the full details?

Sign up free to see the agency name, contact info, and the original bid posting link.

Sign Up Free →

Related Bids

Browse More Bids

Healthcare BidsGRANT BidsClosing Soon All Bids